A 52-week open-label randomized trial found once-weekly semaglutide reduced LDL cholesterol and shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in obese type 2 diabetes. PICO summary and expert commentary.
A secondary lipidomic analysis of two randomized crossover feeding trials found that lowering dietary saturated fat reshaped the lipoprotein(a) lipidome while plasma Lp(a) rose. PICO summary and expert commentary.
A randomized trial in 112 veterans found that immediate return of confirmed familial hypercholesterolemia genetic results plus telegenetic counseling did not significantly reduce LDL-C versus delayed return. PICO summary and expert commentary.
CARDS demonstrated that atorvastatin 10 mg reduces major cardiovascular events by 37% and stroke by 48% in patients with type 2 diabetes and normal to mildly elevated LDL-cholesterol without prior CVD, confirming that cardiovascular risk rather than LDL level should determine statin initiation and establishing universal statin use in primary cardiovascular prevention for type 2 diabetes.
HPS demonstrated that simvastatin reduces major vascular events by 24% across all high-risk patients regardless of baseline LDL-cholesterol level, including those with diabetes without established coronary disease, eliminating the treatment threshold concept and establishing absolute cardiovascular risk as the primary criterion for statin therapy — one of the most influential results in preventive cardiology.
WOSCOPS demonstrated that pravastatin reduces the combined incidence of nonfatal MI and coronary death by 31% in men with hypercholesterolaemia and no prior MI, establishing the primary prevention indication for statin therapy and providing the first large randomised evidence for population-level lipid lowering in high-risk individuals without established cardiovascular disease.
The 4S trial demonstrated that simvastatin reduces all-cause mortality by 30%, coronary death by 42%, and major coronary events by 34% in patients with established coronary heart disease and no excess non-cardiovascular mortality, resolving the safety debate and establishing statin therapy as the standard of care in secondary cardiovascular prevention.
An 8-week RCT finds a hibiscus-inulin shot produces small reductions in lipid-glucose indices in overweight adults, but the authors stress these reflect analytical responsiveness, not proven clinical benefit. PICO summary and commentary.
A four-arm RCT finds exercise plus broccoli sprouts improves apolipoproteins in men with type 2 diabetes, but the benefit is mainly exercise-driven. PICO summary and commentary.
A lipidomics analysis from the randomised EmDia trial finds empagliflozin remodels plasma lipids in type 2 diabetes, raising beneficial LPCs but also harmful ceramides. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
